Advertisement
Advertisement
VTGN
Vistagen Therapeutics, Inc. Common Stock
0.56
USDSponsored
+0.06
+11.09%
Feb 06, 15:59 UTC -5
Closed
After-Market
0.54
-0.02
-3.39%
VTGN Earnings Reports
Positive Surprise Ratio
VTGN beat 19 of 37 last estimates.
51%
Next Report
In 3 Days
Date of Next Report
Feb 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$373.32K
/-$0.49
Implied change from Q2 26 (Revenue/ EPS)
+44.70%
/-9.26%
Implied change from Q3 25 (Revenue/ EPS)
+59.54%
/+6.52%
Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, VTGN reported earnings of -0.54 USD per share (EPS) for Q2 26, missing the estimate of -0.48 USD, resulting in a -11.23% surprise. Revenue reached 258.00 thousand, compared to an expected 248.20 thousand, with a 3.95% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 373.32 thousand USD, implying an decrease of -9.26% EPS, and increase of 44.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Vistagen Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Vistagen Therapeutics, Inc. Common Stock reported EPS of -$0.54, missing estimates by -11.23%, and revenue of $258.00K, 3.95% above expectations.
How did the market react to Vistagen Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved -- 0%, changed from $3.80 before the earnings release to $3.80 the day after.
When is Vistagen Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 11, 2026.
What are the forecasts for Vistagen Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $373.32K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement